Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hnCD16-iNK cells
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
hnCD16-iNK cells are an investigational allogeneic natural killer (NK) cell therapy engineered to express a high-affinity, non-cleavable human CD16 (FcγRIIIA) receptor, designed to enhance antibody-dependent cellular cytotoxicity (ADCC) against tumor cells when combined with therapeutic monoclonal antibodies. By stably augmenting surface CD16, these induced NK (iNK) cells aim to provide potent off-the-shelf cytotoxic activity with improved engagement of IgG1 antibody Fc domains, leveraging NK-cell–mediated killing while minimizing risks of graft-versus-host disease and severe cytokine release syndrome commonly associated with T cell therapies.[3][5]
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)IgG Fc (Immunoglobulin G Fc region)
Beyond the preview
Go deeper on hnCD16-iNK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hnCD16-iNK cells.